[Myelodysplastic syndromes: preleukemic syndromes].
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly patients are associated with a high risk of progression to acute myelogenous leukemia. The etiology of MDS is unknown in most cases. About 10% of MDSs are secondary. MDS are classified by the French American British (FAB) classification into five subgroups. The incidence of the disorders is difficult to estimate but it seems to be increasing. Clonal cytogenetic aberrations are found in 30 to 50% of de novo MDS. The only currative treatment for MDS is allogeneic bone marrow transplantation.
Tassin
F
F
Service d'Hématologie biologique, Université de Liège.
Hermanne
J P
JP
Schaaf-Lafontaine
N
N
Herens
C
C
Thiry
A
A
Paulus
J M
JM
Boniver
J
J
Fillet
G
G
D000368:Aged; D001773:Blood Cells / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002869:Chromosome Aberrations / Q000235:genetics; D002999:Clone Cells / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D011289:Preleukemia / Q000145:classification / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors